Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Meet Masoudi: Deputy Counsel Brings Antitrust Experience To FDA

This article was originally published in The Gray Sheet

Executive Summary

FDA Deputy Chief Counsel Gerald Masoudi can be expected to reinforce the agency's aggressive stance toward product liability suits that encroach on its regulatory authority

You may also be interested in...



People In Brief

FDA top lawyer: Gerald F. Masoudi is FDA's new chief counsel, the agency says Oct. 16. He replaces Sheldon Bradshaw, who resigned from the post to go into private practice in September. Masoudi has been with the Department of Justice since 2005, but prior to that he was FDA deputy chief counsel under Daniel Troy. He served as acting chief counsel when Troy left in November 2004 until Bradshaw took over the following April (1"The Gray Sheet" Nov. 15, 2004, p. 9)

People In Brief

FDA top lawyer: Gerald F. Masoudi is FDA's new chief counsel, the agency says Oct. 16. He replaces Sheldon Bradshaw, who resigned from the post to go into private practice in September. Masoudi has been with the Department of Justice since 2005, but prior to that he was FDA deputy chief counsel under Daniel Troy. He served as acting chief counsel when Troy left in November 2004 until Bradshaw took over the following April (1"The Gray Sheet" Nov. 15, 2004, p. 9)

FDA Chief Counsel Bradshaw Brings DoJ Experience, Utah Political Ties

Sheldon Bradshaw brings high-level government experience and strong political connections to the top legal position at FDA

Related Content

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel